Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“[39] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM,”
BackgroundMethodSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 3×
“[19] Jack CR Jr, Knopman DS, Jaqust WJ, Shaw LM, Aisen PS, Weiner MW, et al.”
BackgroundMethodInfluentialSelf-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“[27] Walsh DM, Selkoe DJ.”
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Doty, R. L., Shaman, P., & Dann, M. (1984) · Physiology & Behavior · doi:10.1016/0031-9384(84)90269-5 · Cited by 1,854
Larson, E. B., Wang, L., Bowen, J. D., McCormick, W. C., Teri, L., Crane, P., & Kukull, W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00004 · Cited by 1,463 · cited 2×
“[4] Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P,”
Background
Cited by
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
“, MAPT using FCSRT [252,263]); a composite score [244,245,253]; or a conversion to MCI [2,246] or dementia [250,256,264,265].”
MethodSelf-citationHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Marsh, S. E., Abud, E. M., Lakatos, A., Karimzadeh, A., Yeung, S. T., Davtyan, H., Fote, G. M., Lau, L., Weinger, J. G., Lane, T. E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525466113 · Cited by 411
Advances in the prevention of Alzheimer's disease and dementia
Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D. A., Breteler, M., Fratiglioni, L., Hooshmand, B., Khachaturian, A. S., Schneider, L. S., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12178 · Cited by 319
Self-citationDown syndrome and Alzheimer's disease: common pathways, common goals
Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290
“Clearly the DS and the Alzheimer’s communities will benefit from the crosstalk in these clinical trials and the advanced trials being conducted in the AD field, including the Dominantly Inherited Alzheimer’s Network Trial Unit (DIAN-TU), the Anti-Amyloid Asymptomatic Alzheimer’s Trial (A4), the TOMMORROW trial, and th…”
BackgroundSelf-citation
Metadata
- Authors
- Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H. H., Siemers, E. R., Abushakra, S., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., & Sperling, R. A.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2013-02-14
- Volume
- 9
- Issue
- 2
- Pages
- 123
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2120903663
- Cited by
- 124
- References
- 31
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2012.12.004
- The paper
- Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H. H., Siemers, E. R., Abushakra, S., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., & Sperling, R. A. (2013). Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2012.12.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.